secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0001437749-25-001569
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx regains Nasdaq compliance; appoints Mike Taylor director amid $25M HOPE investment term sheet
--------------------------------------------------------------------------------

- Received Nasdaq notice on Jan 17 that it regained MVLS compliance; requirement met on Jan 16 after 10 consecutive trading days above $35M.
- Appointed Mike Taylor as Class I director, filling vacancy from Janet Rehnquist resignation, effective Jan 15.
- Taylor designated by JGS Holdings per term sheet for $25M in HOPE Series A Preferred convertible into 1/3 of HOPE equity and $2M for 730k NRXP shares.
- Nasdaq closed the matter, removing delisting risk from the Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/0001437749-25-001569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/nrxp20250122_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-001569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer